Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
BPC-157 , also known as Body Protection Compound-157, is a synthetic pentadecapeptide developed in the early 1990s
A 2025 pilot study infused up to 20 mg of BPC157 intravenously in 2 healthy adults and reported no adverse effects and no abnormal changes in heart, liver, kidney, thyroid, or bloodglucose markers
2.3 DSS-induced models and GHK-Cu treatment DSS is extensively utilized in animal models of UC due to its capacity to induce histopathological, clinical, and immunologic responses that closely resemble the manifestations observed in patients with IBD ( 2.4 Evaluation of colitis Throughout the animal experiment, the mental state, stool consistency, fur quality, perianal condition, and fecal occult blood of the experimental mice were assessed daily at a fixed time
There are potentially significant advantages of small-molecule therapies: their non-injectable format could lead to greater patient compliance
Clin Infect Dis (1997) 24:104851
US$ 21.64
US$ 25.56
US$ 22.22
US$ 23.98
US$ 29.09
US$ 28.80
US$ 21.42
US$ 26.59
US$ 22.84
US$ 23.45
US$ 29.51
